CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2012-03-26): FDA adds diabetes, memory loss warnings to statins

Regulatory

FDA adds diabetes, memory loss warnings to statins

Last Updated: 2012-03-26 18:32:19 -0400 (Reuters Health)

(Reuters) - U.S. health regulators will add warnings to the labels of statins to indicate that they may cause hyperglycemia and memory loss.

The Food and Drug Administration said the new information should not scare people into stopping taking the drugs.

"The value of statins in preventing heart disease has been clearly established," Amy Egan, deputy director for safety in FDA's Division of Metabolism and Endocrinology Products, said in a statement. "Their benefit is indisputable, but they need to be taken with care and knowledge of their side effects."

The FDA said it was aware of studies in which some patients taking statins may have a small increased risk of hyperglycemia and of being diagnosed with type 2 diabetes.

The statin labels will also now reflect reports of certain cognitive effects such as memory loss and confusion experienced by some patients taking the drugs, the agency said. It said those reports generally have not been serious and the symptoms were reversed by stopping use of the statin.

One safety warning long associated with the class of medicines will be reversed, the FDA said: Patients taking statins will no longer need routine periodic monitoring of liver enzymes.

"FDA has concluded that serious liver injury with statins is rare and unpredictable in individual patients, and that routine periodic monitoring of liver enzymes does not appear to be effective in detecting or preventing this rare side effect," it said.

The agency also said Merck's Mevacor (lovastatin) should never be taken with HIV protease inhibitors and drugs used to treat certain bacterial and fungal infections due to increased risk of myopathy or rhabdomyolysis.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.